Delivery Order 75F40121D00032-75F40126F19004

<p>The Food and Drug Administration issued a $309,073.26 delivery order to Integrated Behavioral Health, Inc. on September 28, 2026, for post-marketing prescription drug abuse surveillance data under Executive Order 14398.</p> <p>Place of performance is Silver Spring, Maryland. The order is firm fixed price with an ultimate completion date of September 27, 2027.</p>

The Food and Drug Administration (FDA) awarded a $1.05M firm-fixed-price delivery order to Integrated Behavioral Health, Inc. to conduct research understanding the prevalence, experiences, knowledge, and perceptions of falsified and unapproved pharmaceuticals among populations being assessed for or entering substance use disorder treatment. The work will be performed in Silver Spring, Maryland, with an ultimate completion date of September 28, 2027. This delivery order was awarded without a...

The Food and Drug Administration issued a BPA call to Research Triangle Institute on September 16, 2022, with a ceiling value of $499,770.00 for a patient preference study in opioid use disorder. The call was placed under the FDA's Quick Turnaround Social Science Research Services BPA (valued at $70 million through December 2030). The task order commissions a study to understand the perspectives of patients, family members, and healthcare providers affected by opioid use disorder. Work is...

<p>The Defense Logistics Agency issued a $1,409 delivery order to Amerisourcebergen Drug Corp on May 22, 2026, for buprenorphine 2 mg tablets (30-count), with final delivery due May 26, 2026.</p> <p>Place of performance is Conshohocken, PA. The order is firm fixed-price with no set-aside and carries a ceiling value of $1,409.</p>

The Food and Drug Administration issued a delivery order to Denver Health And Hospital Authority on September 30, 2021, with a ceiling value of $695,889 for data resources supporting post-marketing surveillance of nonmedical use of pharmaceuticals and illicit drug substances under Executive Order 14398. Ultimate completion is scheduled for December 29, 2026. Place of performance is Denver, CO. The order is priced on a firm fixed-price basis with no set-aside. Service Contract Inventory reporting...

<p>The Defense Logistics Agency Medical Supply Chain issued a $1,536.47 delivery order to Fisher Scientific Company L.L.C. on May 12, 2026, for buprenorphine supplies under fixed-price-with-economic-price-adjustment terms, with ultimate completion on May 19, 2026.</p> <p>Place of performance is Pittsburgh, PA. The order carries no set-aside designation.</p>

The National Institute on Drug Abuse issued a delivery order to The Emmes Company, LLC on May 21, 2025, under the NIDA Data, Statistics, and Clinical Trial Support Center IDV (N01DA-22-2253) for data and statistical analysis supporting GLP-1 as an adjunct to buprenorphine. The order ceiling is $1,747,574.58, with performance through February 29, 2028. The NIDA Data, Statistics, and Clinical Trial Support Center is a $44.3 million single-award IDV providing biostatistical analysis, data...

The Substance Abuse and Mental Health Services Administration issued a $29.7 million delivery order to Hendall Inc. on March 15, 2026, under a partial small business set-aside for the Behavioral Health Services Information System (BHSIS) Bridge Contract. Place of performance is Rockville, MD. The order carries a firm fixed-price structure with an ultimate completion date of March 14, 2027. ICF Incorporated serves as subcontractor, providing services and other direct costs to support contract...

This is a Firm Fixed Price delivery order awarded by the Department of Health and Human Services Food and Drug Administration (HHS/FDA) to Inflexxion, Inc., a for-profit organization. The contract, with a potential value of $754,500.62, is for a DATA ENHANCEMENT PROJECT under the FDA Prescription Drug Abuse Summary Reports Master IDIQ contract vehicle. The project aims to provide DATA RESOURCE FOR POST-MARKETING PRESCRIPTION AND OVER-THE-COUNTER DRUG ABUSE SURVEILLANCE DATA. The contract does...

The National Institute on Drug Abuse issued a delivery order to The Emmes Company, LLC on August 15, 2024, under the NIDA Data, Statistics, and Clinical Trial Support Center IDV (N01DA-22-2253) for optimizing retention, duration, and discontinuation strategies for opioid use disorder pharmacotherapy (CTN-0100), with a ceiling value of $1.86 million and ultimate completion date of March 31, 2028. The NIDA Data, Statistics, and Clinical Trial Support Center is a single-award IDV valued at $44.3...